Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.77 |
| ▸ | NME4 | O00746 | 2/20 | 0.77 |
| ▸ | GCDH | Q92947 | 2/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.77 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.77 |
| ▸ | HTR3A | P46098 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | BLVRB | P30043 | 2/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipsalazide SCHEMBL11165440 | 1.00 | SIRT5 (0.77) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL3267109 | 0.87 | SIRT5 (1.00) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL29377041 | 0.87 | SIRT5 (1.00) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL138311 | 0.87 | SIRT5 (1.00) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL118300 | 0.87 | SIRT5 (1.00) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL134019 | 0.86 | SIRT5 (0.97) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL7908058 | 0.86 | SIRT5 (0.97) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL28818120 | 0.86 | SIRT5 (0.97) | SIRT5TDP1HRH3NME4GCDH | |
| Balsalazide SCHEMBL5598491 | 0.86 | SIRT5 (0.97) | SIRT5TDP1HRH3NME4GCDH | |
| SCHEMBL11160268 | 0.85 | SIRT5 (0.79) | SIRT5TDP1HRH3NME4GCDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | EMORY UNIVERSITY (US) | 2024-04-23 | — | — | US | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | claimed |
| EP-3091967-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS | Sigmoid Pharma Limited (IE) | 2016-11-16 | — | — | EP | claimed |
| CN-106132400-A | Composition for treating ulcerative colitis | 希格默伊德药业有限公司 | 2016-11-16 | — | — | CN | claimed |
| WO-2015104414-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS | SIGMOID PHARMA LIMITED (IE) | 2015-07-16 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130231308-A1 | USE OF AMINOSALICYLATES IN DIARRHOEA-PREDOMINENT IRRITABLE BOWEL SYNDROME | SHORTIS NICOLAS PETER (AU) | 2013-09-05 | — | — | US | claimed |
| EP-2361620-A1 | Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome | PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST (AU) | 2011-08-31 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2005030173-A1 | COLON-SPECIFIC DRUG DELIVERY USING INTERPOLYMER COMPLEXATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | WO | claimed |
| EP-0980246-A4 | THERAPY FOR CONSTIPATION | BORODY THOMAS J (AU) | 2004-04-14 | — | — | EP | claimed |
| US-20030138399-A1 | Anti-inflammatory therapy for inflammatory mediated infection | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-07-24 | — | — | US | claimed |
| JP-2002544210-A | — | — | 2002-12-24 | — | — | JP | claimed |
| CN-1353573-A | Anti-inflammatory therapy for inflammatory mediated infection | UNIV CALIFORNIA (US) | 2002-06-12 | — | — | CN | claimed |
| EP-1202620-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | The Regents of the University of California (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2000069255-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-23 | — | — | WO | claimed |
| EP-0980246-A1 | THERAPY FOR CONSTIPATION | BORODY, Thomas Julius (AU) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050043-A1 | NOVEL THERAPY FOR CONSTIPATION | BORODY THOMAS J (AU) | 1998-11-12 | — | — | WO | claimed |
| US-4412992-A | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith | BIOREX LABORATORIES LIMITED (GB) | 1983-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231308-A1 | USE OF AMINOSALICYLATES IN DIARRHOEA-PREDOMINENT IRRITABLE BOWEL SYNDROME | SLC10A2, SI, ABAT | SIRT5 2290/4885TDP1 2325/4885HRH3 444/4885 |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | SIRT5 635/4885TDP1 653/4885HRH3 1096/4885 |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | SAMHD1, PNP, NUDT1 | SIRT5 635/4885TDP1 653/4885HRH3 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.